Skip to content
AnalystLens

3M CO 8-K Report, Financial Results (Oct 21, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 21, 2025
Period End
October 21, 2025
Security
MMM
In the record · 2016–202610-K1110-Q338-K187

MMM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 187 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’18Nov ’18
  2. Material agreement8-K · Nov ’20Nov ’20
  3. Impairment8-K · Dec ’22Dec ’22
  4. Material agreement8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed October 21, 2025. Cited figures are marked; the original filing is the authoritative source.

3M reported third-quarter 2025 results on October 21, 2025 that were solid at the adjusted level and showed improving operating leverage.

GAAP net sales were $6.5 billiona, up 3.5% year-over-year, with organic growth of 2.6%. Adjusted sales were $6.3 billion, up 4.1%, with adjusted organic growth of 3.2%. Adjusted operating margin expanded 170 basis points to 24.7%, and adjusted EPS rose 10% to $2.19.

GAAP EPS fell 38% to $1.55b, driven mainly by litigation costs, a $0.30 loss on business divestitures, and a $0.13 mark-to-market charge on the Solventum stake, all of which 3M excludes from adjusted results. Adjusted operating cash flow was $1.8 billion and adjusted free cash flow was $1.3 billion. Management raised full-year 2025 guidance.

Adjusted EPS is now expected at $7.95 to $8.05c, up from $7.75 to $8.00. Adjusted operating margin expansion is now 180 to 200 basis points, and adjusted organic sales growth is guided above 2%. Adjusted free cash flow is expected at $4.3 to $4.5 billion.

The raise reflects the company's operational progress in the first nine months of the year. Investors should weigh the gap between GAAP and adjusted results. Nine-month GAAP operating cash flow was only $723 milliond, compared with $3.7 billion adjusted, because of large cash outflows for PFAS and Combat Arms Earplugs litigation settlements.

Third-quarter GAAP cash flow was positive at $1.76 billion, which helped offset that drag. The balance sheet shows cash falling to $4.7 billion from $5.6 billion at year-end 2024, while long-term debt rose to $11.9 billion. Share repurchases of $2.7 billion in the first nine months were partly funded by $1.2 billion from stock option exercises.

02—Key points

Key Highlights

  1. Adjusted EPS of $2.19 rose 10% year-over-year, while GAAP EPS of $1.55 fell 38% amid litigation, divestiture, and Solventum-related special items.
  2. Adjusted operating income margin reached 24.7%, up 170 basis points, with GAAP operating margin at 22.2%, up 130 basis points.
  3. Adjusted organic sales grew 3.2% in Q3 (GAAP organic growth 2.6%), indicating an improving top-line trend after weaker prior periods.
  4. Full-year 2025 adjusted EPS guidance raised to $7.95–$8.05 from $7.75–$8.00, and adjusted margin expansion guided to 180–200 bps.
  5. Nine-month GAAP operating cash flow was only $723 million versus $3.7 billion adjusted, reflecting large litigation payments that are excluded from adjusted free cash flow.
  6. Cash and equivalents declined to $4.7 billion and long-term debt rose to $11.9 billion, while $2.7 billion of buybacks in the first nine months were partly funded by $1.2 billion of option proceeds.
  7. Q3 included a $0.30 per share loss on business divestitures, with a write-down on a business held for sale, plus a $0.13 per share charge from the decline in value of the retained Solventum stake.

03—Questions

Frequently Asked Questions

  1. Why did GAAP EPS fall 38% while adjusted EPS rose 10%?

    GAAP EPS of $1.55 compares with $2.48 a year earlier, which included a $1.05 per share gain from the rise in value of the Solventum stake. Q3 2025 GAAP results also absorbed $0.19 of significant litigation costs, $0.30 of divestiture losses, $0.13 of Solventum mark-to-market losses, and $0.02 of transformation costs. Adjusted EPS strips out these items, so it shows underlying growth of 10% to $2.19.

  2. Is the full-year guidance raise meaningful for investors?

    Yes, though the change is modest. Adjusted EPS guidance moved up by $0.05 at the midpoint, from $7.75–$8.00 to $7.95–$8.05. Margin expansion guidance of 180–200 bps and organic growth above 2% indicate management expects continued operational improvement. Because the company does not forecast GAAP EPS, investors cannot compare the guidance to a GAAP baseline.

  3. Why is operating cash flow so much weaker on a GAAP basis than on an adjusted basis?

    Nine-month GAAP operating cash flow was $723 million, while adjusted operating cash flow was $3.7 billion. The difference is mainly about $3.0 billion of after-tax payments tied to litigation settlements, including PFAS and Combat Arms Earplugs matters, which 3M excludes from its adjusted measures. Investors should treat these payments as real cash outflows, since 3M expects full-year adjusted free cash flow of $4.3–$4.5 billion, and litigation payments remain a material ongoing obligation.

  4. What does the business divestiture loss signal about 3M's portfolio strategy?

    The Q3 loss of $161 million pre-tax reflects a write-down on a business classified as held for sale, and a small divestiture completed in Q2 for proceeds slightly below book value. Management is pursuing portfolio pruning, including exiting PFAS manufacturing by the end of 2025. Investors should watch for further write-downs and whether the divestitures are accretive to margins over time.

04—Continue

← View all 8-K filings